MyLeukemiaTeam

Yes, this is good news! The absence of TP53 alterations and chromosome 17p deletions is a positive finding. These genetic changes are typically associated with poorer outcomes and treatment resistance in CLL/SLL patients. Not having these mutations means you're more likely to respond better to traditional treatments Show Full Answer

Yes, this is good news! The absence of TP53 alterations and chromosome 17p deletions is a positive finding. These genetic changes are typically associated with poorer outcomes and treatment resistance in CLL/SLL patients. Not having these mutations means you're more likely to respond better to traditional treatments. Patients without these genetic changes generally have more treatment options available to them. While those with TP53 or 17p deletions often need to use specific targeted therapies, you may be eligible for a broader range of treatment approaches. This gives your healthcare team more flexibility in designing your treatment plan.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Chronic Lymphocytic Leukemia Survival Rate and Outlook

Oral Therapy vs. Traditional Chemotherapy for CLL/SLL